Jubilant Life Seeks Shareholders' Nod To Raise Upto Rs 1,000 Crore
This approval to the board to raise the amount also stipulates that this could be done in one or more series/tranches during a period of one year from the date of passing the resolution, it added. Notice of Postal Ballot
Jubilant Life Sciences Ltd has submitted to BSE a Copy of the Notice of Postal Ballot. Exercise of ESOP Options
Jubilant Life Sciences Ltd has informed BSE that 1,500 options under Jubilant Employees Stock Option Plan 2005 (Plan 2005) and 1,850 options under JLL Employees Stock Option Plan 2011 (Plan 2011) have been exercised by the option holders.Pursuant to the terms of Plan 2005 and Plan 2011, the Nomination, Remuneration and Compensation Committee of the Company (the Committee") has approved transfer of 9,350 equity shares of Re. 1 each of... Intimation of Schedule of Investor/Analyst meetings on November 16,17 and 18, 2016
Jubilant Life Sciences Ltd has informed BSE regarding "Intimation of Schedule of Investor/Analyst meetings on November 16,17 and 18, 2016". Intimation of schedule of meetings of Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Life Sciences Limited with Fixed Income Investors
Jubilant Life Sciences Ltd has informed BSE regarding "Intimation of schedule of meetings of Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Life Sciences Limited with Fixed Income Investors". Issuance of Commercial Papers of Rs. 50 crore
Jubilant Life Sciences Ltd has informed BSE that the Company has issued Commercial Papers of Rs. 50 crore on November 09, 2016, having maturity date of December 29, 2016, which have been rated IND A1 + by India Ratings & Research Private Limited.The aggregate amount of Commercial Papers outstanding as on date is Rs. 100 crore. ANDA approval may activate Jubilant Life
Shares of Jubilant Life Sciences may remain active, as the company has received final approval for the generic version of Crestor tablets from the US Food and Drug Administration. It has received... Jubilant Life Sciences receives ANDA approval for Rosuvastatin Calcium Tablets
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated November 01, 2016, titled "Jubilant Life Sciences receives ANDA approval for Rosuvastatin Calcium Tablets".
Jubilant Life Q2 net up 14.51% at Rs145 crore
Jubilant Life Sciences posted a net profit after taxes, minority interest and share of profit/loss of associates of Rs126.42 crore for the corresponding period of the previous fiscal Outcome of Board Meeting
Jubilant Life Sciences Ltd has informed BSE that at the meeting of the Board of Directors of the Company (the Board) held on October 27, 2016 at 1:30 p.m. and concluded at 3:15 p.m., inter alia, the following decisions have, been taken:- The Board has decided to obtain, an enabling approval from the shareholders of the Company through Postal Ballot for issuance of Redeemable Non-Convertible Debentures on private placement basis upto an amount of Rs. 1,000 crore.